Syndax Pharmaceuticals, Inc. (SNDX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 10:01AM EDT. Market open.
| Previous Close | 21.97 |
| Open | 22.10 |
| Bid | 21.71 x 200 |
| Ask | 21.93 x 100 |
| Day's Range | 21.50 - 22.10 |
| 52 Week Range | 11.22 - 25.34 |
| Volume | |
| Avg. Volume | 1,074,190 |
| Market Cap | 1.854B |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.24 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.18 |
PR NewswireSyndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.
- GuruFocus.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Insights into SNDX's robust pipeline progress, financial health, and strategic plans for upcoming drug launches.
PR NewswireSyndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the quarter ended March 31, 2024, and provided a business update.
© 2024 Yahoo. All rights reserved.